Top

Published in:

01-12-2019 | Acute Myeloid Leukemia | Letter to the Editor

Acute myeloid leukemia with a cryptic NUP98/PRRX2 rearrangement developing after low-dose methotrexate therapy for rheumatoid arthritis

Authors: Kazuhisa Chonabayashi, Yoshinori Yoshida, Toshio Kitawaki, Yasuhito Nannya, Momoko Nakamura, Shinichiro Oshima, Masakatsu Hishizawa, Kouhei Yamashita, Seishi Ogawa, Akifumi Takaori-Kondo

Published in: Annals of Hematology | Issue 12/2019

Excerpt

Dear Editor, …

Struski S, Lagarde S, Bories P, Puiseux C, Prade N, Cuccuini W, Pages MP, Bidet A, Gervais C, Lafage-Pochitaloff M, Roche-Lestienne C, Barin C, Penther D, Nadal N, Radford-Weiss I, Collonge-Rame MA, Gaillard B, Mugneret F, Lefebvre C, Bart-Delabesse E, Petit A, Leverger G, Broccardo C, Luquet I, Pasquet M, Delabesse E (2017) NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. Leukemia 31(3):565–572. https://doi.org/10.1038/leu.2016.267 CrossRefPubMed

Gervais C, Mauvieux L, Perrusson N, Helias C, Struski S, Leymarie V, Lioure B, Lessard M (2005) A new translocation t(9;11)(q34;p15) fuses NUP98 to a novel homeobox partner gene, PRRX2, in a therapy-related acute myeloid leukemia. Leukemia 19(1):145–148. https://doi.org/10.1038/sj.leu.2403565 CrossRefPubMed

Romana SP, Radford-Weiss I, Ben Abdelali R, Schluth C, Petit A, Dastugue N, Talmant P, Bilhou-Nabera C, Mugneret F, Lafage-Pochitaloff M, Mozziconacci MJ, Andrieu J, Lai JL, Terre C, Rack K, Cornillet-Lefebvre P, Luquet I, Nadal N, Nguyen-Khac F, Perot C, Van den Akker J, Fert-Ferrer S, Cabrol C, Charrin C, Tigaud I, Poirel H, Vekemans M, Bernard OA, Berger R, Groupe Francophone de Cytogenetique H (2006) NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogenetique Hematologique. Leukemia 20(4):696–706. https://doi.org/10.1038/sj.leu.2404130 CrossRefPubMed

Pointud P, Prudat M, Peron JM (1993) Acute leukemia after low dose methotrexate therapy in a patient with rheumatoid arthritis. J Rheumatol 20(7):1215–1216PubMed

Tanaka K, Oshikawa G, Akiyama H, Ishida S, Nagao T, Yamamoto M, Miura O (2017) Acute myeloid leukemia with t(3;21)(q26.2;q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report. Oncol Lett 14(1):97–102. https://doi.org/10.3892/ol.2017.6151 CrossRefPubMedPubMedCentral

Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, van Galen JF, Beverloo HB, Sonneveld E, Kaspers GJ, Trka J, Baruchel A, Zimmermann M, Creutzig U, Reinhardt D, Pieters R, Valk PJ, Zwaan CM (2011) NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 118(13):3645–3656. https://doi.org/10.1182/blood-2011-04-346643 CrossRefPubMed

Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S (2014) NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood 124(15):2400–2407. https://doi.org/10.1182/blood-2014-04-570929 CrossRefPubMedPubMedCentral

Reader JC, Meekins JS, Gojo I, Ning Y (2007) A novel NUP98-PHF23 fusion resulting from a cryptic translocation t(11;17)(p15;p13) in acute myeloid leukemia. Leukemia 21(4):842–844. https://doi.org/10.1038/sj.leu.2404579 CrossRefPubMed

de Rooij JD, Hollink IH, Arentsen-Peters ST, van Galen JF, Berna Beverloo H, Baruchel A, Trka J, Reinhardt D, Sonneveld E, Zimmermann M, Alonzo TA, Pieters R, Meshinchi S, van den Heuvel-Eibrink MM, Zwaan CM (2013) NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia 27(12):2280–2288. https://doi.org/10.1038/leu.2013.87 CrossRefPubMed

Title: Acute myeloid leukemia with a cryptic NUP98/PRRX2 rearrangement developing after low-dose methotrexate therapy for rheumatoid arthritis
Authors: Kazuhisa Chonabayashi
Yoshinori Yoshida
Toshio Kitawaki
Yasuhito Nannya
Momoko Nakamura
Shinichiro Oshima
Masakatsu Hishizawa
Kouhei Yamashita
Seishi Ogawa
Akifumi Takaori-Kondo
Publication date: 01-12-2019
Publisher: Springer Berlin Heidelberg
Keywords: Acute Myeloid Leukemia
Fluorescence in Situ Hybridization
Alkylating Agent
Methotrexate
Methotrexate
Rheumatoid Arthritis
Published in: Annals of Hematology / Issue 12/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-019-03838-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Acute myeloid leukemia with a cryptic NUP98/PRRX2 rearrangement developing after low-dose methotrexate therapy for rheumatoid arthritis

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2019

Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis

Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-α

Response to interferon treatment in essential thrombocythemia with inv(3)(q21q26)

Residual methylation of tumor suppressor gene promoters, RASSF6 and RASSF10, as novel biomarkers for minimal residual disease detection in adult acute lymphoblastic leukemia

RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group

Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page